+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy



Targeting CD9 produces stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis: a novel antiangiogenic therapy



Biochemical and Biophysical Research Communications 413(1): 128-135



The precise roles of tetraspanin CD9 are unclear. Here we show that CD9 plays a stimulus-independent role in angiogenesis and that inhibiting CD9 expression or function is a potential antiangiogenic therapy. Knocking down CD9 expression significantly inhibited in vitro endothelial cell migration and invasion induced by vascular endothelial growth factor (VEGF) or hepatocyte growth factor (HGF). Injecting CD9-specific small interfering RNA (siRNA-CD9) markedly inhibited HGF- or VEGF-induced subconjunctival angiogenesis in vivo. Both results revealed potent and stimulus-independent antiangiogenic effects of targeting CD9. Furthermore, intravitreous injections of siRNA-CD9 or anti-CD9 antibodies were therapeutically effective for laser-induced retinal and choroidal neovascularization in mice, a representative ocular angiogenic disease model. In terms of the mechanism, growth factor receptor and downstream signaling activation were not affected, whereas abnormal localization of integrins and membrane type-1 matrix metalloproteinase was observed during angiogenesis, by knocking down CD9 expression. Notably, knocking down CD9 expression did not induce death and mildly inhibited proliferation of quiescent endothelial cells under conditions without an angiogenic stimulus. Thus, CD9 does not directly affect growth factor-induced signal transduction, which is required in angiogenesis and normal vasculature, but is part of the angiogenesis machinery in endothelial cells during angiogenesis. In conclusion, targeting CD9 produced stimulus-independent antiangiogenic effects predominantly in activated endothelial cells during angiogenesis, and appears to be an effective and safe antiangiogenic approach. These results shed light on the biological roles of CD9 and may lead to novel antiangiogenic therapies.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 036185188

Download citation: RISBibTeXText

PMID: 21875571

DOI: 10.1016/j.bbrc.2011.08.068


Related references

Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic microRNA-17-92 cluster in endothelial cells. Arteriosclerosis, Thrombosis, and Vascular Biology 33(3): 533-543, 2013

A mathematical model of the contribution of endothelial progenitor cells to angiogenesis in tumors: implications for antiangiogenic therapy. Blood 102(7): 2555-2561, 2003

A novel VEGF-independent antiangiogenic therapy targeting the CD160 receptor. Medecine Sciences 28(1): 37-38, 2012

Antiangiogenic Resistance: Novel Angiogenesis Axes Uncovered by Antiangiogenic Therapies Research. Current Drug Targets 17(15): 1728-1734, 2016

Antiangiogenic therapy targeting factors that enhance endothelial cell survival. Seminars in Oncology 29(3 Suppl 11): 96-103, 2002

Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Clinical Advances in Hematology and Oncology 1(1): 41-48, 2005

Endothelial Side Population Cells Contribute to Tumor Angiogenesis and Antiangiogenic Drug Resistance. Cancer Research 76(11): 3200-3210, 2017

Tylophorine, a phenanthraindolizidine alkaloid isolated from Tylophora indica exerts antiangiogenic and antitumor activity by targeting vascular endothelial growth factor receptor 2-mediated angiogenesis. Molecular Cancer 12: 82, 2013

Aosp5 Tylophorine, A Phenanthraindolizidine Alkaloid Isolated From Tylophora Indica, Exerts Antiangiogenic And Antitumour Activity By Targeting Vascular Endothelial Growth Factor Receptor 2-Mediated Angiogenesis. European Journal of Cancer 49: S8-S9, 2013

MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. Plos One 6(2): E16979, 2012

Antiangiogenic Effect of Rosiglitazone Is Mediated via Peroxisome Proliferator-activated Receptor -activated Maxi-K Channel Opening in Human Umbilical Vein Endothelial Cells. Journal of biological chemistry12 281(19): 13503-13512, 2006

Antiangiogenic activity of indole-3-carbinol in endothelial cells stimulated with activated macrophages. Food Chemistry 134(2): 811-820, 2013

Antiangiogenic effect of rosiglitazone is mediated via peroxisome proliferator-activated receptor gamma-activated maxi-K channel opening in human umbilical vein endothelial cells. Journal of Biological Chemistry 281(19): 13503-13512, 2006

Antiangiogenic therapy: preclinical premise and promise: Biological Basis for Antiangiogenic Therapy, Milan, Italy, 810 November 1999. Molecular Medicine Today 6(5): 188-189, 2000

Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Current Cancer Drug Targets 5(4): 229-248, 2005